The 72 references in paper V. Arkhipov V., V. Prozorova K., D. Arkhipova E., В. Архипов В., В. Прозорова К., Д. Архипова Е. (2014) “Сочетание бронхиальной астмы и хронической обструктивной болезни легких // Co-morbidity of bronchial asthma and chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2013:i:4:p:87-94

1
Han M.K., Agusti A., Calverley P.M. et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182 (5): 598–604.
(check this in PDF content)
2
Cottini M., Asero R. Asthma phenotypes today. Eur. Ann. Allergy Clin. Immunol. 2013; 45 (1): 17–24.
(check this in PDF content)
3
Editorial. Asthma: still more questions than answers. Lancet 2008; 372 (9643): 1009.
(check this in PDF content)
4
Miravitlles M., Soler3Cataluna J.J., Calle M. et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch. Bronconeumol. 2012; 48 (7): 247–257.
(check this in PDF content)
5
Global strategy for asthma management and prevention. Updated December 2012. http://www.ginasthma.org/docu3 ments/4
(check this in PDF content)
6
Gallefoss F, Bakke P.Does smoking affect the outcome of patient education and self management in asthmatics? Patient Educ. Couns. 2003; 49: 91–97.
(check this in PDF content)
7
Schayck O.C., Haughney J., Aubier M. et al. Do asthmatic smokers benefit as much as non-smokers on budesonide / formoterol maintenance and reliever therapy? Results of an open label study. Respir. Med. 2012; 106 (2): 189–196.
(check this in PDF content)
8
Aubier M., Buhl R., Ekstrom T. et al. Comparison of two twice-daily doses of budesonide / formoterol maintenance and reliever therapy. Eur. Respir. J. 2010; 36: 524–530.
(check this in PDF content)
9
Eisner M.D., Yelin E.H., Trupin L., Blanc P.D. Asthma and smoking status in a population-based study of California adults. Publ. Hlth Rep. 2001; 116 (2): 148–157.
(check this in PDF content)
10
Pedersen S.E., Bateman E.D., Bousquet J. et al.Determinants of response to fluticasone propionate and salmeterol / fluticasone propionate combination in the Gaining Optimal Asthma controL study. J. Allergy Clin. Immunol. 2007; 120 (5): 1036–1042.
(check this in PDF content)
11
Chaudhuri R., Livingston E., McMahon A.D. et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am. J. Respir. Crit. Care Med. 2003; 168 (11): 1308–1311.
(check this in PDF content)
12
Chalmers G.W., Macleod K.J., Little S.A. et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57 (3): 226–230.
(check this in PDF content)
13
O'Byrne P.M., Lamm C.J., Busse W.W. et al. The effects of inhaled budesonide on lung function in smokers and nonsmokers with mild persistent asthma. Chest 2009; 136 (6): 1514–1520.
(check this in PDF content)
14
Chaudhuri R., Livingston E., McMahon A.D. et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am. J. Respir. Crit. Care Med. 2006; 174 (2): 127–133.
(check this in PDF content)
15
Barnes P.J., Adcock I.M., Ito K.Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. 2005; 25 (3): 552–563.
(check this in PDF content)
16
Higenbottam T., Feyeraband C., Clark T.Cigarette smoking in asthma. Br. J. Dis. Chest 1980; 74: 279–284.
(check this in PDF content)
17
Dijkstra A., Vonk J.M., Jongepier H. et al. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Thorax 2006; 61 (2): 105–110.
(check this in PDF content)
18
Vestbo J., Edwards L.D., Scanlon P.D. et al.Changes in forced expiratory volume in 1 second over time in COPD. N. Engl. J. Med. 2011; 365 (13): 1184–1192.
(check this in PDF content)
19
Lange P., Scharling H., Ulrik C.S., Vestbo J.Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax 2006; 61 (2): 100–104.
(check this in PDF content)
20
Kerstjens H.A., Overbeek S.E., Schouten J.P. et al. Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. Eur. Respir. J. 1993; 6 (6): 868–876.
(check this in PDF content)
21
Chalmers G., MacLeod K., Thomson L. et al. Smoking and airway inflammation in patients with mild asthma. Chest 2001; 120: 1917–1922.
(check this in PDF content)
22
Chalmers G.W., Macleod K.J., Little S.A. et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57 (3): 226–230.
(check this in PDF content)
23
Green R.H., Brightling C.E., Woltmann G. et al.Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57: 875–879.
(check this in PDF content)
24
Dima E., Rovina N., Gerassimou C. et al. Pulmonary function tests, sputum induction, and bronchial provocation tests: diagnostic tools in the challenge of distinguishing asthma and COPD phenotypes in clinical practice. Int. J. Chron. Obstruct. Pulm. Dis. 2010; 5: 287–296.
(check this in PDF content)
25
Wenzel S.E.Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Med. 2012; 18 (5): 716–725.
(check this in PDF content)
26
Федосеев Г.Б., Хлопотова Г.П.Бронхиальная астма. Л.: Медицина; 1988.
(check this in PDF content)
27
Barnes P.J., Woolcock A.J. Difficult asthma. Eur. Respir. J. 1998; 12 (5): 1209–1218.
(check this in PDF content)
28
Fahy J.V. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc. Am. Thorac. Soc. 2009; 6 (3): 256–259.
(check this in PDF content)
29
Lange P., Parner J., Vestbo J. et al.A 15-year follow-up study of ventilatory function in adults with asthma. N. Engl. J. Med. 1998; 339: 1194–1200.
(check this in PDF content)
30
Sorkness R., Bleecker E., Busse W. et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J. Appl. Physiol. 2008; 104: 394–403.
(check this in PDF content)
31
Paganin F., Seneterre E., Chanez P. et al. Computed tomography of the lungs in asthma: influence of disease severity and etiology. Am. J. Respir. Crit. Care Med. 1996; 153: 110–114.
(check this in PDF content)
32
Barnes P.J.Inhaled corticosteroids in COPD: a controversy. Respiration 2010; 80 (2): 89–95.
(check this in PDF content)
33
Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1977; 1 (6077): 1645–1648.
(check this in PDF content)
34
Kohansal R., Martinez3Camblor P., Agusti A. et al.The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am. J. Respir. Crit. Care Med. 2009; 180 (1): 3–10.
(check this in PDF content)
35
Celli B.R., Thomas N.E., Anderson J.A. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178 (4): 332–338.
(check this in PDF content)
36
Halpin D., Decramer M., Celli B. et al. Impact of a single chronic obstructive pulmonary disease (COPD) exacerbation on lung function decline: Analysis of UPLIFT. In: European Respiratory Society (ERS). 2012 Annual congress. 2012: Abstract 194OC. Presented September 2, 2012.
(check this in PDF content)
37
Vestbo J., Edwards L.D., Scanlon P.D. et al. Changes in forced expiratory volume in 1 second over time in COPD. N. Engl. J. Med. 2011; 365 (13): 1184–1192.
(check this in PDF content)
38
Mahler D.A., Wire P., Horstman D. et al.Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir Crit. Care Med. 2002; 166 (8): 1084–1091.
(check this in PDF content)
39
Donohue J.F., Anderson W., Wisniewski M. et al. Demographics and bronchoreversibility of salmeterol and ipratropium in a large population of patients with mild-to-moderate COPD [abstract]. Am. J. Respir. Crit. Care Med.1997; 155: A227.
(check this in PDF content)
40
Dorinsky P.M., Reisner C., Ferguson G.T. et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999; 115: 966–971.
(check this in PDF content)
41
Calverley P.M., Burge P.S., Spencer S. et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58 (8): 659–664.
(check this in PDF content)
42
Watt A.P., Schock B.C., Ennis M. Neutrophils and eosinophils: clinical implications of their appearance, presence and disappearance in asthma and COPD. Curr. Drug Targets. Inflamm. Allergy 2005; 4 (4): 415–423.
(check this in PDF content)
43
Brightling C.E., Monteiro W., Ward R. et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000; 356 (9240): 1480–1485.
(check this in PDF content)
44
Bafadhel M., McKenna S., Terry S. et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebocontrolled trial. Am. J. Respir. Crit. Care Med. 2012; 186 (1): 48–55.
(check this in PDF content)
45
Siva R., Green R., Briqthlinq C. et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur. Respir. J. 2007; 29: 906–913.
(check this in PDF content)
46
Oraka E., Kim H.J., King M.E., Callahan D.B. Asthma prevalence among US elderly by age groups: age still matters. J. Asthma 2012; 49 (6): 593–599.
(check this in PDF content)
47
Sherrill D., Guerra S., Bobadilla A., Barbee R.The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics. Eur. Respir. J. 2003; 21 (1): 95–100.
(check this in PDF content)
48
Schneider A., Tilemann L., Schermer T. et al. Diagnosing asthma in general practice with portable exhaled nitric oxide measurement – results of a prospective diagnostic study: FENO < or = 16 ppb better than FENO < or =12 ppb to rule out mild and moderate to severe asthma [added]. Respir. Res. 2009; 10: 15.
(check this in PDF content)
49
Cazzola M., Puxeddu E., Bettoncelli G. et al. The prevalence of asthma and COPD in Italy: a practice-based study. Respir. Med. 2011; 105 (3): 386–391.
(check this in PDF content)
50
Viegi G., Matteelli G., Angino A. et al. The proportional Venn diagram of obstructive lung disease in the Italian general population. Chest 2004; 126 (4): 1093–1101.
(check this in PDF content)
51
Soriano J.B., Davis K.J., Coleman B. et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003; 124 (2): 474–481.
(check this in PDF content)
52
Mannino D.M., Gagnon R.C., Petty T.L., Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988–1994. Arch. Intern. Med. 2000; 160 (11): 1683–1689.
(check this in PDF content)
53
Haahtela T., Tuomisto L.E., Pietinalho A. et al.A 10 year asthma programme in Finland: major change for the better. Thorax 2006; 61: 663–670.
(check this in PDF content)
54
Kim T.B., Oh Y.M., Chang Y.S. et al.The reality of an intermediate type between asthma and COPD in practice. Respir. Care 2012; 57 (8): 1248–1253.
(check this in PDF content)
55
Soler3Cataluna J.J., Cosio B., Izquierdo J.L. et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch. Bronconeumol. 2012; 48 (9): 331–337.
(check this in PDF content)
56
Duggal R., Menkes D.B.Evidence-based medicine in practice. Int. J. Clin. Pract. 2011; 65 (6): 639–644.
(check this in PDF content)
57
Sethi S., Mahler D.A., Marcus P. et al.Inflammation in COPD: implications for management. Am. J. Med. 2012; 125 (12): 1162–1170.
(check this in PDF content)
58
Lofdahl C.G., Postma D.S., Pride N.B. et al.Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur. Respir. J. 2007; 29 (6): 1115–1119.
(check this in PDF content)
59
Loke Y.K, Kwok C.S., Singh S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur. Respir. J. 2010; 35 (5):1003–1021. doi: 10.1183/09031936.00095909.
(check this in PDF content)
60
Stallberg B., Selroos O., Vogelmeier C. et al. Budesonide / formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir. Res. 2009; 10: 11.
(check this in PDF content)
61
Malmstrom K., Rodriguez3Gomez G., Guerra J. et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast / Beclomethasone Study Group. Ann. Intern. Med. 1999; 130 (6): 487–495.
(check this in PDF content)
62
Berge M., ten Hacken N.H., Cohen J. et al.Small airway disease in asthma and COPD: clinical implications. Chest 2011; 139 (2): 412–423.
(check this in PDF content)
63
To Y., Kharitonov S., Adcock I. et al.Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline. In: Program and abstracts of the European Respiratory Society 15thAnnual congress, September 17–21, 2005. Copenhagen, 2005. Abstr. 215.
(check this in PDF content)
64
Dolovich M. New delivery systems and propellants. Can. Respir. J. 1999; 6 (3): 290–295.
(check this in PDF content)
65
Backer W., Devolder A., Poli G. et al. Lung deposition of BDP / formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J. Aerosol Med. Pulm. Drug Deliv. 2010; 23 (3): 137–148.
(check this in PDF content)
66
Brusselle G., Peche R., Van den Brande P. et al.Real-life effectiveness of extrafine beclometasone dipropionate / formoterol in adults with persistent asthma according to smoking status. Respir. Med. 2012; 106 (6): 811–819.
(check this in PDF content)
67
O'Connor B.J., Collarini S., Poli G. et al. Rapid effects of extrafine beclomethasone dipropionate / formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial. BMC Pulm. Med. 2011; 11: 60.
(check this in PDF content)
68
Tzani P., Crisafulli E., Nicolini G. et al. Effects of beclomethasone / formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 503–509. Обзоры
(check this in PDF content)
69
Singh D., Kampschulte J., Wedzicha J.A. et al. A trial of beclomethasone / formoterol in COPD using EXACT-PRO to measure exacerbations. Eur. Respir. J. 2013; 41 (1): 12–17.
(check this in PDF content)
70
Spears M., Donnelly I., Jolly L. et al.Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur. Respir. J. 2009; 33: 1010–1017.
(check this in PDF content)
71
Novelli F., Malagrino L., Dente F.L., Paggiaro P.Efficacy of anticholinergic drugs in asthma. Expert. Rev. Respir. Med. 2012; 6 (3): 309–319.
(check this in PDF content)
72
Kerstjens H.A., Engel M., Dahl R. et al. Tiotropium in asthma poorly controlled with standard combination therapy. N. Engl. J. Med. 2012; 367 (13): 1198–1207. Информация об авторах Архипов Владимир Владимирович – д. м. н., профессор кафедры кли-
(check this in PDF content)